Ibrutinib | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Ibrutinib
Health Canada Patents

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

Contact Supplier

IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

Contact Supplier

IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

Contact Supplier

PharmaCompass Sponsored Ads

Contact Supplier

Coral

Contact Supplier

ICE Pharma offers a unique range of bile acid products and best-in-class services for the pharmaceutical industry.

Contact Supplier

Ibrutinib

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

57 API Suppliers, 19 USDMF, 5 EU WC, 1 KDMF, 16 NDC API, 39 Listed Suppliers, $ API Reference Price

57 API Suppliers
19 USDMF
5 EU WC
1 KDMF
16 NDC API
39 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

298 Drugs in Development

298 Drugs in Development

INTERMEDIATES

44 Intermediate Suppliers

44 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

85 FDF Dossiers, 31 FDA Orange Book, 18 Europe, 2 Canada, 19 Australia, 5 South Africa, 10 Listed Dossiers

85 FDF Dossiers
31 FDA Orange Book
18 Europe
2 Canada
19 Australia
5 South Africa
10 Listed Dossiers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 1 Stock Recap #PipelineProspector, 252 News #PharmaBuzz

1 Data Compilation #PharmaFlow
1 Stock Recap #PipelineProspector
252 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 4 Regulatory FDF Prices, 20 Annual Reports

1 US Medicaid Prescriptions
4 Regulatory FDF Prices
20 Annual Reports

MARKET PLACE

5 APIs, 5 FDF Dossiers

5 APIs
5 FDF Dossiers

PATENTS & EXCLUSIVITIES

702 US Patents, 36 US Exclusivities, 51 Health Canada Patents

702 US Patents
36 US Exclusivities
51 Health Canada Patents

REF. STANDARDS & IMPURITIES

14 Others

14 Others

$ API Ref.Price (USD/KG) : 6,050 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

51 All

01 51Belmore Neidrauer LLP

filter Patent Reset all filters

51 All

01 62663116

02 42800913

03 52851808

04 62875986

05 52928721

06 42976695

07 12991994

08 43007787

09 53007788

10 63015208

11 53022256

filter Product Reset all filters

51 All

01 51IBRUTINIB

filter Dosage Reset all filters

51 All

01 10CAPSULE

02 4SUSPENSION

03 37TABLET

filter Exp Date Reset all filters

51 All

01 62026-12-28

02 182031-06-03

03 52032-10-19

04 132033-06-03

05 52034-10-24

06 42036-03-02

Product Main Page

01

Belmore Neidrauer LLP

IBRUTINIB

Formnext Forum

Not Confirmed

Belmore Neidrauer LLP

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-12-28

Date Granted : 2014-06-10

Brand Name : IMBRUVICA

Patent Number : 2663116

Filing Date : 2006-12-28

Strength per Unit : 140 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2026-12-28

Date Granted : 2014-06-10

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Belmore Neidrauer LLP

IBRUTINIB

Formnext Forum

Not Confirmed

Belmore Neidrauer LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2031-06-03

Date Granted : 2019-07-23

Brand Name : IMBRUVICA

Patent Number : 2800913

Filing Date : 2011-06-03

Strength per Unit : 140 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2031-06-03

Date Granted : 2019-07-23

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

03

Belmore Neidrauer LLP

IBRUTINIB

Formnext Forum

Not Confirmed

Belmore Neidrauer LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2031-06-03

Date Granted : 2020-03-10

Brand Name : IMBRUVICA

Patent Number : 3007788

Filing Date : 2011-06-03

Strength per Unit : 140 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2031-06-03

Date Granted : 2020-03-10

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

Belmore Neidrauer LLP

IBRUTINIB

Formnext Forum

Not Confirmed

Belmore Neidrauer LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2034-10-24

Date Granted : 2020-12-22

Brand Name : IMBRUVICA

Patent Number : 2928721

Filing Date : 2014-10-24

Strength per Unit : 140 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2034-10-24

Date Granted : 2020-12-22

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

05

Belmore Neidrauer LLP

IBRUTINIB

Formnext Forum

Not Confirmed

Belmore Neidrauer LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-06-03

Date Granted : 2020-06-09

Brand Name : IMBRUVICA

Patent Number : 2875986

Filing Date : 2013-06-03

Strength per Unit : 140 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2033-06-03

Date Granted : 2020-06-09

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

06

Belmore Neidrauer LLP

IBRUTINIB

Formnext Forum

Not Confirmed

Belmore Neidrauer LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-12-28

Date Granted : 2014-06-10

Brand Name : IMBRUVICA

Patent Number : 2663116

Filing Date : 2006-12-28

Strength per Unit : 140 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2026-12-28

Date Granted : 2014-06-10

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

07

Belmore Neidrauer LLP

IBRUTINIB

Formnext Forum

Not Confirmed

Belmore Neidrauer LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2031-06-03

Date Granted : 2019-07-23

Brand Name : IMBRUVICA

Patent Number : 2800913

Filing Date : 2011-06-03

Strength per Unit : 140 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2031-06-03

Date Granted : 2019-07-23

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

08

Belmore Neidrauer LLP

IBRUTINIB

Formnext Forum

Not Confirmed

Belmore Neidrauer LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2031-06-03

Date Granted : 2020-03-10

Brand Name : IMBRUVICA

Patent Number : 3007788

Filing Date : 2011-06-03

Strength per Unit : 140 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2031-06-03

Date Granted : 2020-03-10

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

09

Belmore Neidrauer LLP

IBRUTINIB

Formnext Forum

Not Confirmed

Belmore Neidrauer LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2034-10-24

Date Granted : 2020-12-22

Brand Name : IMBRUVICA

Patent Number : 2928721

Filing Date : 2014-10-24

Strength per Unit : 140 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2034-10-24

Date Granted : 2020-12-22

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

10

Belmore Neidrauer LLP

IBRUTINIB

Formnext Forum

Not Confirmed

Belmore Neidrauer LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-06-03

Date Granted : 2020-06-09

Brand Name : IMBRUVICA

Patent Number : 2875986

Filing Date : 2013-06-03

Strength per Unit : 140 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2033-06-03

Date Granted : 2020-06-09

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

1
2
3
Last

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!